Elicio Therapeutics (ELTX) Cost of Revenue (2020 - 2021)
Elicio Therapeutics posted quarterly Cost of Revenue of $433000.0 for Q4 2021, up 243.65% year-on-year from $126000.0 in Q4 2020, and up 243.65% on a QoQ basis from $126000.0 in Q4 2020.
Elicio Therapeutics (ELTX) has 2 years of Cost of Revenue data on file, last reported at $433000.0 in Q4 2021.
- For the quarter ending Q4 2021, Cost of Revenue rose 243.65% year-over-year to $433000.0; the trailing twelve-month figure through Dec 2021 stood at $433000.0 (down 63.61% YoY), and the FY2021 full-year result was $433000.0, down 63.61% from the prior year.
- Cost of Revenue for Q4 2021 stood at $433000.0, up from $126000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $433000.0 in Q4 2021 and bottomed at $126000.0 in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 64.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 392.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 296.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 207.52 Mn |
| 10 | Elicio Therapeutics | 217.63 Mn | 202.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 433,000.00 |
| Dec 31, 2021 | 433,000.00 |
| Dec 31, 2020 | 126,000.00 |
| Dec 31, 2020 | 126,000.00 |
| Sep 30, 2020 | 348,000.00 |
| Sep 30, 2020 | 348,000.00 |
| Jun 30, 2020 | 333,000.00 |
| Jun 30, 2020 | 333,000.00 |
| Mar 31, 2020 | 383,000.00 |
| Mar 31, 2020 | 383,000.00 |